US Patent

US10017491 — Compounds and uses thereof for the modulation of hemoglobin

Formulation · Assigned to Global Blood Therapeutics Inc · Expires 2032-12-28 · 7y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds and pharmaceutical compositions for modulating hemoglobin, including methods for their preparation and use in treating various disorders.

USPTO Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Drugs covered by this patent

Patent Metadata

Patent number
US10017491
Jurisdiction
US
Classification
Formulation
Expires
2032-12-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Global Blood Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.